Form 4: Inmune Bio Director Timothy Schroeder Acquires 32,500 Stock Options

Director Timothy Schroeder of Inmune Bio, Inc. was granted 32,500 stock options on December 5, 2024, which will vest in two years.

Summary

• Timothy Schroeder, a director at Inmune Bio, Inc., was granted 32,500 stock options on December 5, 2024.
• The options have an exercise price of $5.05 per share.
• These options were granted under the company's 2021 Stock Incentive Plan.
• The options will fully vest and become exercisable on December 5, 2026, which is two years after the grant date.
• The options expire on December 4, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard corporate practice of granting stock options to a director, which is generally viewed positively as it aligns interests. There is no indication of any negative or unexpected events.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders.
• The vesting period of two years encourages long-term commitment from the director.

Industry Context

Stock option grants are a common practice for incentivizing directors and aligning their interests with the long-term performance of the company.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for directors in publicly traded companies.
• The two-year vesting period is a typical timeframe for such grants, designed to encourage long-term commitment and performance.

Stakeholder Impact

• The stock option grant may be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.

Key Dates

Keywords

stock options, insider trading, equity, Inmune Bio, director, vesting, stock incentive plan